SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NVIDIA Corp. engages in the design and manufacture of computer graphics processors, chipsets, and related multimedia software. It operates through the following segments: Graphics Processing Unit (GPU) and Compute & Networking. The Graphics segment includes GeForce GPUs for gaming and PCs, the GeForce NOW game streaming service and related infrastructure, Quadro and NVIDIA RTX GPUs for enterprise workstation graphics, virtual GPU, or vGPU, software for cloud-based visual and virtual computing, automotive platforms for infotainment systems, and Omniverse Enterprise software for building and operating metaverse and 3D internet applications. The Compute & Networking segment consists of Data Center accelerated computing platforms and end-to-end networking platforms including Quantum for InfiniBand and Spectrum for Ethernet, NVIDIA DRIVE automated-driving platform and automotive development agreements, Jetson robotics and other embedded platforms, NVIDIA AI Enterprise and other software, and DGX Cloud software and services. The company was founded by Jen Hsun Huang, Chris A. Malachowsky, and Curtis R. Priem in April 1993 and is headquartered in Santa Clara, CA.

NVIDIA Corp

Nvidias selloff is largely tied to concern that calls for tighter AI rules and resistance to data-center construction could slow infrastructure spending and GPU demand; traders also debate whether the AI buildout is overextended and reliant on circular financing. Bulls view the decline as an overreaction, arguing that demand will persist and projects can move elsewhere, while bears question the sustainability and timing of future spending.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

A tech-led selloff has QQQ traders focused on fears that the Democratic midterm sweep could bring tighter AI and data-center rules, potentially slowing investment; some also see a broader unwind of stretched AI valuations and crowded positions. The community is sharply divided between calls of capitulation and an AI bubble popping, and traders looking to buy the dip or expecting a rebound.

Sandisk Corp. engages in the development, manufacture, and provision of storage devices and solutions based on NAND flash technology. Its products include solid state drives, memory cards, and USB flash drives. The company was founded on February 5, 2024 and is headquartered in Milpitas, CA.

Sandisk Corp

Concerns that Democratic control of Congress could bring tighter AI and data-center regulation have fueled a sharp selloff in SanDisk and other memory and semiconductor stocks, alongside broader worries about AI-trade de-risking and memory cyclicality. Traders are split between expecting further downside and buying the dip, with some arguing that strong earnings and memory demand remain intact.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

A sharp semiconductor selloff, magnified by SOXLs 3x daily leverage, is being linked by traders to fears that the Democrats midterm gains could bring tighter AI and data-center rules and slow chip investment. The community is split between claims that the AI trade is breaking down and buyers who view the political fears as overblown and the decline as capitulation.

Micron Technology, Inc. engages in the provision of innovative memory and storage solutions. It operates through the following segments: Cloud Memory Business Unit (CMBU), Core Data Center Business Unit (CDBU), Mobile and Client Business Unit (MCBU), and Automotive and Embedded Business Unit (AEBU). The CMBU segment focuses on memory solutions for large hyperscale cloud customers and High-Bandwidth Memory for all data center customers. The CDBU segment is involved in memory solutions for mid-tier cloud, enterprise, and OEM data center customers and storage solutions for all data center customers. The MCBU segment focuses on memory and storage solutions for the mobile and client segments. The AEBU segment is involved in memory and storage solutions for the automotive, industrial, and consumer segments. The company was founded by Ward D. Parkinson, Joseph Leon Parkinson, Dennis Wilson, and Doug Pitman on October 5, 1978 and is headquartered in Boise, ID.

Micron Technology Inc.

Micron Technology Inc

Fears that a Democratic sweep and calls for tighter AI regulation could slow data-center expansion are driving a sharp selloff in Micron and other chip stocks. Traders are split between concerns that weaker AI infrastructure spending could hurt memory demand and views that the reaction is overblown because demand and Microns fundamentals remain strong.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is caught in a broader AI and semiconductor selloff, as traders worry that political calls for AI regulation and tighter data-center rules could slow the buildout. The drop has frustrated traders who point to strong results and guidance, while others argue that high valuations and doubts about AI spending make the sector vulnerable.

AppLovin Corp. engages in the development and operation of a mobile marketing platform. It offers AppDiscovery, MAX, Adjust, and SparkLabs. Its software-based platform caters to mobile application developers to improve the marketing and monetization of applications. The company was founded by Andrew Karam, John Krystynak, and Adam Foroughi in 2011 and is headquartered in Palo Alto, CA.

Applovin Corp - Ordinary Shares - Class A

Applovin Corp

AppLovins record Q3 results, stronger-than-expected Q4 outlook, and expanded share buyback sparked a sharp rally, with traders also pointing to improving performance from its AI advertising models. The community is largely celebrating the rebound, while some warn the move may fade and question whether the growth can be sustained.

SPDR S&P 500 ETF TRUST - SPDR S&P 500 ETF Trust

A sharp reversal after the post-midterm rally dominates discussion, with traders linking the selloff to fears that Democratic control could constrain AI and data-center expansion. Others point to stretched AI valuations and a rotation out of tech, while dip buyers argue the decline is overdone.

Nebius Group NV is a technology company that provides infrastructure and services to AI builders worldwide. It offers Nebius AI, an AI-centric cloud platform provides full-stack infrastructure, including large-scale GPU clusters, cloud services, and developer tools. The company also operates through specialized brands: Toloka AI, which partners in data for generative AI development; TripleTen, an edtech platform focused on re-skilling individuals for tech careers; and Avride, which develops autonomous driving technology. Nebius Group was founded by Elena Kolmanovskaya, Ilya Segalovich, Mikhail Fadeev, and Arkady Volozh in 1989 and is headquartered in Amsterdam, the Netherlands.

Nebius Group N.V. - Ordinary Shares - Class A

Nebius Group N.V. 

Fears that Democratic election gains could bring tighter regulation, permitting hurdles, or a slower U.S. data-center buildout are weighing on Nebius and other AI infrastructure stocks. Traders are split between viewing the selloff as an overreaction and buying opportunitysome argue Nebius has limited exposure to the states in focusand warning that delays, financing needs, and broader AI-trade weakness could prolong the pressure.

Broadcom Inc. is a global technology company, which designs, develops, and supplies semiconductors and infrastructure software solutions. It operates through the Semiconductor Solutions and Infrastructure Software segments. The Semiconductor Solutions segment refers to product lines and intellectual property licensing. The Infrastructure Software segment relates to mainframe, distributed and cyber security solutions, and fibre channel storage area networking business. The company was founded in 1961 and is headquartered in Palo Alto, CA.

Broadcom Inc

Broad semiconductor and AI-stock selling has intensified concerns that hyperscalers heavy, debt-funded data-center spending may not earn adequate returns or continue at the same pace, leaving Broadcom exposed to a small group of major customers. Traders are debating that risk against bullish arguments that AI investment and Anthropic-related commitments support demand; the conversation is dominated by frustration over the decline, alongside some dip-buying.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Novavaxs third-quarter results, higher full-year revenue outlook and milestone tied to Sanofis Phase 3 flu-COVID combination trial are driving attention. Traders welcomed the improved financial outlook and cost cuts, but many remain disappointed by the lack of a new partnership or concrete pipeline updates, especially on oncology.

The move appears tied to Novavaxs third-quarter results and a $145 million increase to its 2026 adjusted revenue guidance, lifting the midpoint to $400 million. The company also reported a $125 million milestone from Sanofis launch of a Phase 3 influenza-COVID-19 combination vaccine trial in Europe.

Novavax Reports Third Quarter 2026 Financial Results and Operational Highlights

Novavax Reports Third Quarter 2026 Financial Results and Operational Highlights Novavax Reports Third Quarter 2026 Financial Results and Operational HighlightsPR NewswireGAITHERSBURG, Md., Nov. 5, 2026 Reports total revenue of $68 million for the third quarter of 2026Raises full-year 2026 Non-GAAP...

Novavax Earns $125 Million Milestone as Sanofi Launches Phase 3 Influenza-COVID-19 Combination Vaccine Trial in Europe

Novavax Earns $125 Million Milestone as Sanofi Launches Phase 3 Influenza-COVID-19 Combination Vaccine Trial in Europe Novavax Earns $125 Million Milestone as Sanofi Launches Phase 3 Influenza-COVID-19 Combination Vaccine Trial in EuropePR NewswireGAITHERSBURG, Md., Oct. 29, 2026 The global flu and...

Novavax (NVAX) May Report Negative Earnings: Know the Trend Ahead of Q3 Release

Novavax (NVAX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Novavax to Report Third Quarter 2026 Financial Results on November 5, 2026

Novavax to Report Third Quarter 2026 Financial Results on November 5, 2026 Novavax to Report Third Quarter 2026 Financial Results on November 5, 2026PR NewswireGAITHERSBURG, Md., Oct. 29, 2026 GAITHERSBURG, Md., Oct. 29, 2026 /PRNewswire/ -- Novavax, Inc. (Nasdaq: NVAX) today announced that the...

Novavax (NVAX) Stock Falls Amid Market Uptick: What Investors Need to Know

Novavax (NVAX) concluded the recent trading session at $9.4, signifying a -3.09% move from its prior day's close.

Biogen (BIIB) Surges 5.3%: Is This an Indication of Further Gains?

Biogen (BIIB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to Know

Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Novavax (NVAX) Stock Declines While Market Improves: Some Information for Investors

Novavax (NVAX) concluded the recent trading session at $10.82, signifying a -3.91% move from its prior day's close.

Novavax (NVAX) Increases Despite Market Slip: Here's What You Need to Know

In the most recent trading session, Novavax (NVAX) closed at $12.82, indicating a +1.26% shift from the previous trading day.

Vaccine Stocks Rally on Reports of U.S.-led Push for Cancer Vaccines

MRNA, BNTX and NVAX shares rally after reports of a planned NIH-backed initiative to accelerate personalized cancer vaccines and expand research funding.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

BNTX, NVAX, MRNA Lead Vaccine Rally After Report Of An NIH Cancer-Vaccine Push 

Equity

Bullish Sentiment

<ul class="summary-bullets"><li>The bet is a public-private partnership among the NIH, the nonprofit Foundation for the NIH, researchers, drug and biotech companies, advocacy groups, philanthropies, and patients.</li><li>Stacey Adam, a senior clinical officer at the foundation, told the Times she hopes it will resemble the collaboration that produced COVID shots.</li><li>Cancer vaccines, unlike most other vaccines, are treatments, not preventives.</li></ul> Vaccine stocks rallied on Friday after a report on new details of a national push to speed up personalized cancer vaccines.<a class="mention" data-mention="$NVAX" data-symbol-id="NVAX" href="https://stocktwits.com/symbol/NVAX" target="_blank">Novavax</a> (NVAX) closed up about 16% near $13, Moderna (MRNA) about 14% near $225, and Vaxcyte (PCVX) about 10%. BioNTech (BNTX) was up about 5%, Merck (MRK) about 2%, and Pfizer (PFE) a little more than 2%.&nbsp;Moderna had a second tailwind: it rejoined the Nasdaq-100 before the market open. Vaxcyte was already higher this week on its own pneumococcal vaccine data. Novavax has no cancer-vaccine program but a vaccine platform, and the stock moved on sympathy buying. &nbsp;<h2 class="st-heading-2">NCI Aims To Start A Partnership In December</h2>National Cancer Institute’s director, Dr. Anthony Letai, wants a national effort behind the vaccines, The New York Times <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.nytimes.com/2026/10/09/science/cancer-vaccines-nih-big-bet.html">reported </a>on Friday. “We can place big bets on new ideas,” he said of new resources at the National Institutes of Health.The bet is a public-private partnership among the NIH, the nonprofit Foundation for the NIH, researchers, drug and biotech companies, advocacy groups, philanthropies, and patients. Stacey Adam, a senior clinical officer at the foundation, told the paper that she hopes it will resemble the collaboration that produced COVID shots.She said the program is expected to begin in December, starting with pancreatic, liver, and colorectal cancers, plus a subset of pediatric tumors. Adam’s goal is that within seven to ten years a patient could get a vaccine in a doctor’s office, faster than the eight to 15 years she said approval can take when the work is fragmented.<h2 class="st-heading-2">Merck, Moderna, And BioNTech Already Have Shots In Trials</h2>Cancer vaccines, unlike most other vaccines, are treatments, not preventives. Each is built for one patient, meant to train T cells to attack abnormal proteins found on that person’s tumor and nowhere else. Most use mRNA, a technology the newspaper noted had fallen out of favor with the Trump administration.The furthest along in cancer vaccines is Merck and Moderna’s personalized mRNA vaccine, intismeran autogene, also called V940. In a study of 1,137 people with advanced melanoma, the companies said in August that the shot plus Keytruda lengthened the time before cancers returned and before they spread.That is the only cancer-vaccine trial large enough so far to show definitive results. The full dataset is due at the ESMO meeting in Madrid on October 24, and the partners are also testing the approach in other tumors, including lung and bladder cancer.&nbsp;BioNTech is the other main public name. With Genentech, it is developing autogene cevumeran: a small pancreatic-cancer study found that seven of eight patients who responded to the vaccine were still alive after as long as six years of follow-up, against two of eight who did not respond, and a 260-patient trial began in 2023. BioNTech is also advancing separate cancer-vaccine programs, including BNT113 and BNT116.<h2 class="st-heading-2">How Did Retail Traders React?</h2>On Stocktwits, retail sentiment around MRNA and NVAX was 'bullish' at the time of writing, while sentiment around BNTX, MRK and PFE was either 'bearish' or 'neutral.'While MRNA stock has added over 660% year-to-date, MRK has gained 38%. NVAX has added 90%, and BNTX has added 2%.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/mrna-stock-sets-new-52-week-high-as-nasdaq-100-reentry-meets-nih-cancer-vaccine-push/cZxGGuoRBnj">MRNA Stock Sets New 52-Week High As Nasdaq-100 Reentry Meets NIH Cancer-Vaccine Push</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

National Cancer Institute’s director, Dr. Anthony Letai, wants a national effort behind the vaccines, The New York Times reported on Friday.

BNTX, NVAX, MRNA Lead Vaccine Rally After Report Of An NIH Cancer-Vaccine Push

National Cancer Institute’s director, Dr. Anthony Letai, wants a national effort behind the vaccines, The New York Times reported on Friday.


BioNTech SE - ADR

Merck & Co Inc

Moderna Inc

Novavax Inc

Pfizer Inc

More bullish

No change

More bearish

Too early to tell

Following the midterm results, how are you feeling about the market?

Stocktwits

Stocktwits Polls

Investors are weighing the positive Q3 revenue beat and guidance hike against concerns over long-term profitability and partnership timing.

Shareholders are clamoring for major licensing deals, specifically looking for new oncology partnerships or breakthroughs beyond the Sanofi alliance.

High short interest is fueling speculation about a potential rally, as traders look for any positive catalyst to force position closures.

The potential application of the Matrix-M adjuvant in diverse disease targets remains a core, though highly speculative, long-term thesis.

Current Price	$10.11
Prev Close	$10.65
Open	$10.33
Dividend Yield	0.00%
50-Day Moving Average	$10.51
Beta	1.58
Avg. Volume	8.63M
PE Ratio	-6.99

52-Week High	$13.39
52-Week Low	$6.20
Market Capitalization	$1.76B
EPS (Annual)	$2.54
Price to Book	-9.20
Revenue Per Employee	$1.5M

Feed

News

Sentiment

Earnings

Fundamentals

Info

NVAX Fundamentals